|
1
|
Eng C, Yoshino T, Ruíz-García E, Mostafa
N, Cann CG, O'Brian B, Benny A, Perez RO and Cremolini C:
Colorectal cancer. Lancet. 404:294–310. 2024. View Article : Google Scholar
|
|
2
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A Review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Uneyama M, Chambers JK, Nakashima K,
Uchida K and Nakayama H: Histological classification and
immunohistochemical study of feline colorectal epithelial tumors.
Vet Pathol. 58:305–314. 2021. View Article : Google Scholar
|
|
4
|
Marusyk A, Janiszewska M and Polyak K:
Intratumor heterogeneity: The Rosetta Stone of therapy resistance.
Cancer Cell. 37:471–484. 2020. View Article : Google Scholar
|
|
5
|
GBD 2019 Colorectal Cancer Collaborators,
. Global, regional, and national burden of colorectal cancer and
its risk factors, 1990–2019: A systematic analysis for the global
burden of disease study 2019. Lancet Gastroenterol Hepatol.
7:627–647. 2022. View Article : Google Scholar
|
|
6
|
Zygulska AL and Pierzchalski P: Novel
diagnostic biomarkers in colorectal cancer. Int J Mol Sci.
23:8522022. View Article : Google Scholar
|
|
7
|
Gerstberger S, Jiang Q and Ganesh K:
Metastasis. Cell. 186:1564–1579. 2023. View Article : Google Scholar
|
|
8
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
9
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar
|
|
10
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar
|
|
11
|
Rui R, Zhou L and He S: Cancer
immunotherapies: advances and bottlenecks. Front Immunol.
14:12124762023. View Article : Google Scholar
|
|
12
|
Naimi A, Mohammed RN, Raji A, Chupradit S,
Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S,
Shomali N, et al: Tumor immunotherapies by immune checkpoint
inhibitors (ICIs); the pros and cons. Cell Commun Signal.
20:442022. View Article : Google Scholar
|
|
13
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin Q, Wu L, Han L, Zheng X, Tong R, Li L,
Bai L and Bian Y: Immune-related adverse events of immune
checkpoint inhibitors: A review. Front Immunol. 14:11679752023.
View Article : Google Scholar
|
|
15
|
Xiao C, Xiong W, Xu Y, Zou J, Zeng Y, Liu
J, Peng Y, Hu C and Wu F: Immunometabolism: A new dimension in
immunotherapy resistance. Front Med. 17:585–616. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawashima S and Togashi Y: Resistance to
immune checkpoint inhibitors and the tumor microenvironment. Exp
Dermatol. 32:240–249. 2023. View Article : Google Scholar
|
|
17
|
Lee J and Zhou P: DCAFs, the missing link
of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 26:775–780. 2007.
View Article : Google Scholar
|
|
18
|
Shan BQ, Wang XM, Zheng L, Han Y, Gao J,
Lv MD, Zhang Y, Liu YX, Zhang H, Chen HS, et al: DCAF13 promotes
breast cancer cell proliferation by ubiquitin inhibiting PERP
expression. Cancer Sci. 113:1587–1600. 2022. View Article : Google Scholar
|
|
19
|
Yan X, Rong M, Zhou Q and Zhang C: DCAF13
is essential for the pathogenesis of preeclampsia through its
involvement in endometrial decidualization. Mol Cell Endocrinol.
556:1117412022. View Article : Google Scholar
|
|
20
|
Zhang YL, Zhao LW, Zhang J, Le R, Ji SY,
Chen C, Gao Y, Li D, Gao S and Fan HY: DCAF13 promotes pluripotency
by negatively regulating SUV39H1 stability during early embryonic
development. EMBO J. 37:e989812018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Li H, Mao A, Lu J, Liu W, Qie J and
Pan G: DCAF13 promotes triple-negative breast cancer metastasis by
mediating DTX3 mRNA degradation. Cell Cycle. 19:3622–3631. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang K, Li L, Fu L, Yuan Y, Dai H, Zhu T,
Zhou Y and Yuan F: Integrated bioinformatics analysis the function
of RNA binding proteins (RBPs) and their prognostic value in breast
cancer. Front Pharmacol. 10:1402019. View Article : Google Scholar
|
|
23
|
Wei S, Xing J, Chen J, Chen L, Lv J, Chen
X, Li T, Yu T, Wang H, Wang K and Yu W: DCAF13 inhibits the p53
signaling pathway by promoting p53 ubiquitination modification in
lung adenocarcinoma. J Exp Clin Cancer Res. 43:32024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang WJ, Hu CL, Guo BL, Liang XP, Wang CY
and Yang T: STAT5B suppresses ferroptosis by promoting DCAF13
transcription to regulate p53/xCT pathway to promote mantle cell
lymphoma progression. Biologics. 18:181–193. 2024.PubMed/NCBI
|
|
25
|
Tang ZY, Wang XM, Xu CW, Sun QQ, Hua YX,
Zhou QY, Hu HY, Liu SB, Guo YJ, Ao L, et al: DCAF13 promotes
ovarian cancer progression by activating FRAS1-mediated FAK
signaling pathway. Cell Mol Life Sci. 81:4212024. View Article : Google Scholar
|
|
26
|
Liu ZY, Li YH, Zhang QK, Li BW and Xin L:
Development and validation of a ubiquitin-proteasome system gene
signature for prognostic prediction and immune microenvironment
evaluation in hepatocellular carcinoma. J Cancer Res Clin Oncol.
149:13363–13382. 2023. View Article : Google Scholar
|
|
27
|
Wei S, Lu K, Xing J and Yu W: A
multidimensional pan-cancer analysis of DCAF13 and its
protumorigenic effect in lung adenocarcinoma. FASEB J.
37:e228492023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou L, Wang S, Hu W, Liu X, Xu L, Tong B,
Zhang T, Xue Z, Guo Y, Zhao J, et al: T cell proliferation requires
ribosomal maturation in nucleolar condensates dependent on DCAF13.
J Cell Biol. 222:e2022010962023. View Article : Google Scholar
|
|
29
|
Sun Y, Baechler SA, Zhang X, Kumar S,
Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, et
al: Targeting neddylation sensitizes colorectal cancer to
topoisomerase I inhibitors by inactivating the DCAF13-CRL4
ubiquitin ligase complex. Nat Commun. 14:37622023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuan H, Yan M, Zhang G, Liu W, Deng C,
Liao G, Xu L, Luo T, Yan H, Long Z, et al: CancerSEA: A cancer
single-cell state atlas. Nucleic Acids Res. 47((D1)): D900–D908.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li D, Zhao W, Zhang X, Lv H, Li C and Sun
L: NEFM DNA methylation correlates with immune infiltration and
survival in breast cancer. Clin Epigenetics. 13:1122021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiang S, Li J, Shen J, Zhao Y, Wu X, Li M,
Yang X, Kaboli PJ, Du F, Zheng Y, et al: Identification of
prognostic genes in the tumor microenvironment of hepatocellular
carcinoma. Front Immunol. 12:6538362021. View Article : Google Scholar
|
|
35
|
Yang S, Wen L, Chai X, Song Y, Chen X,
Chen ZF, Li R, Dong C, Qi Z and Cai Z: The protective effects of
taurine and fish oil supplementation on PM2.5-induced heart
dysfunction among aged mice: A random double-blind study. Sci Total
Environ. 851((Pt 1)): 1579662022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang W, Xie M, Huang Q, Liu H, Liu J, Sun
X and Li C: STEAP3 is a potential preliminary prognostic biomarker
of glioblastoma. Sci Rep. 14:309942024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia Y, Zhang R, Wang M, Li J, Dong J, He
K, Guo T, Ju X, Ru J, Zhang S and Sun Y: Development and validation
of a necroptosis-related gene prognostic score to predict prognosis
and efficiency of immunotherapy in gastric cancer. Front Immunol.
13:9773382022. View Article : Google Scholar
|
|
39
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weiser MR: AJCC 8th Edition: Colorectal
cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar
|
|
41
|
Jin Q, Liu G, Bao L, Ma Y, Qi H, Yun Z,
Dai Y and Zhang S: High Spy1 expression predicts poor prognosis in
colorectal cancer. Cancer Manag Res. 10:2757–2765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang M, Lan S, Song M, Zhang R, Zhang W,
Sun X and Liu G: Synthesis of zinc oxide-doped carbon dots for
treatment of triple-negative breast cancer. Int J Nanomed.
19:13949–13971. 2024. View Article : Google Scholar
|
|
43
|
Zhang R, Lan S, Jia M, Liu F, Wang M, Jin
Q, Su L and Liu G: Theranostic applications of taurine-derived
carbon dots in colorectal cancer: Ferroptosis induction and
multifaceted antitumor mechanisms. Int J Nanomedicine.
20:7613–7635. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu G, Li S, Yuan H, Hao M, Wurihan Yun Z,
Zhao J, Ma Y and Dai Y: Effect of sodium alginate on mouse ovary
vitrification. Theriogenology. 113:78–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang M, Lan S, Zhang W, Jin Q, Du H, Sun
X, He L, Meng X, Su L and Liu G: Anti-Cancer potency of
copper-doped carbon quantum dots against breast cancer progression.
Int J Nanomed. 19:1985–2004. 2024. View Article : Google Scholar
|
|
46
|
Zhang W, Sun J, Liu F, Li S, Wang X, Su L
and Liu G: Alleviative effect of lactoferrin interventions against
the hepatotoxicity induced by titanium dioxide nanoparticles. Biol
Trace Elem Res. 202:624–642. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shin AE, Giancotti FG and Rustgi AK:
Metastatic colorectal cancer: Mechanisms and emerging therapeutics.
Trends Pharmacol Sci. 44:222–236. 2023. View Article : Google Scholar
|
|
48
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar
|
|
49
|
Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao
X and Lu Y: Immunotherapy in colorectal cancer: Current
achievements and future perspective. Int J Biol Sci. 17:3837–3849.
2021. View Article : Google Scholar
|
|
50
|
Kasi PM, Budde G, Krainock M, Aushev VN,
Koyen Malashevich A, Malhotra M, Olshan P, Billings PR and Aleshin
A: Circulating tumor DNA (ctDNA) serial analysis during progression
on PD-1 blockade and later CTLA-4 rescue in patients with mismatch
repair deficient metastatic colorectal cancer. J Immunother Cancer.
10:e0033122022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Salewski I, Kuntoff S, Kuemmel A,
Feldtmann R, Felix SB, Henze L, Junghanss C and Maletzki C:
Combined vaccine-immune-checkpoint inhibition constitutes a
promising strategy for treatment of dMMR tumors. Cancer Immunol
Immunother. 70:3405–3419. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang W, Mei Z, Chen Y, Jiang J, Qu Y,
Saifuding K, Zhou N, Bulibu G, Tang Y, Zhai X and Jiang Z: Immune
checkpoint inhibitors for patients with mismatch repair deficient
or microsatellite instability-high advanced cancers: A
meta-analysis of phase I–III clinical trials. Int J Surg.
111:1357–1372. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kazama K, Otake J, Satoyoshi T, Shiozawa
M, Sugano N, Sato S, Atsumi Y, Kano K, Murakawa M, Maezawa Y, et
al: Distribution of regulatory T-cells and other phenotypes of
T-cells in tumors and regional lymph nodes of colorectal cancer
patients. In Vivo. 34:849–856. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bai Z, Zhou Y, Ye Z, Xiong J, Lan H and
Wang F: Tumor-Infiltrating lymphocytes in colorectal cancer: the
fundamental indication and application on immunotherapy. Front
Immunol. 12:8089642021. View Article : Google Scholar
|
|
56
|
Yamaguchi H, Hsu JM, Sun L, Wang SC and
Hung MC: Advances and prospects of biomarkers for immune checkpoint
inhibitors. Cell Rep Med. 5:1016212024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang C, Wang HN and Wang L: Biomarkers for
predicting the efficacy of immune checkpoint inhibitors. J Cancer.
13:481–495. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mc Neil V and Lee SW: Advancing cancer
treatment: A review of immune checkpoint inhibitors and combination
strategies. Cancers (Basel). 17:14082025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stier A, Gilberto S, Mohamed WI, Royall
LN, Helenius J, Mikicic I, Sajic T, Beli P, Müller DJ, Jessberger S
and Peter M: The CUL4B-based E3 ubiquitin ligase regulates mitosis
and brain development by recruiting phospho-specific DCAFs. EMBO J.
42:e1128472023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jang SM, Redon CE and Aladjem MI:
Switching DCAFs: Beyond substrate receptors. BioEssays.
43:e21000572021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou Z, Song X, Wavelet CM and Wan Y:
Cullin 4-DCAF proteins in tumorigenesis. Adv Exp Med Biol.
1217:241–259. 2020. View Article : Google Scholar
|
|
62
|
Miao Q, Kadam VD, Mukherjee A, Tan Z and
Teng M: Unlocking DCAFs To catalyze degrader development: An arena
for innovative approaches. J Med Chem. 66:13369–13383. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pan WW, Zhou JJ, Yu C, Xu Y, Guo LJ, Zhang
HY, Zhou D, Song FZ and Fan HY: Ubiquitin E3 ligase
CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian
surface epithelial cancer. J Biol Chem. 288:29680–29691. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ghate NB, Kim S, Mehmood R, Shin Y, Kim K
and An W: VprBP/DCAF1 regulates p53 function and stability through
site-specific phosphorylation. Oncogene. 42:1405–1416. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sun Z, Zhou D, Yang J and Zhang D:
Doxorubicin promotes breast cancer cell migration and invasion via
DCAF13. FEBS Open Bio. 12:221–230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang H, Chen Y, Han J, Meng Q, Xi Q, Wu G
and Zhang B: DCAF4L2 promotes colorectal cancer invasion and
metastasis via mediating degradation of NFκb negative regulator
PPM1B. Am J Transl Res. 8:405–418. 2016.PubMed/NCBI
|
|
67
|
Yang C, Wu J, He H and Liu H: Small
molecule NSC1892 targets the CUL4A/4B-DDB1 interactions and causes
impairment of CRL4DCAF4 E3 ligases to inhibit colorectal
cancer cell growth. Int J Biol Sci. 16:1059–1070. 2020. View Article : Google Scholar
|
|
68
|
Kim KT, Lee MH, Shin SJ, Cho I, Kuk JC,
Yun J and Choi YY: Decorin as a key marker of desmoplastic
cancer-associated fibroblasts mediating first-line immune
checkpoint blockade resistance in metastatic gastric cancer.
Gastric Cancer. 28:12–26. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ieranò C, Righelli D, D'Alterio C,
Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM,
Guardascione G, et al: In PD-1+ human colon cancer cells NIVOLUMAB
promotes survival and could protect tumor cells from conventional
therapies. J Immunother Cancer. 10:e0040322022. View Article : Google Scholar
|
|
70
|
Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin
K, Huang Q, Shi X, Ni Z, Ding N, et al: Tumor-infiltrating immune
cells act as a marker for prognosis in colorectal cancer. Front
Immunol. 10:23682019. View Article : Google Scholar
|
|
71
|
Chen Y, Zhao B and Wang X: Tumor
infiltrating immune cells (TIICs) as a biomarker for prognosis
benefits in patients with osteosarcoma. BMC Cancer. 20:10222020.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Qin Y, Liu Y, Xiang X, Long X, Chen Z,
Huang X, Yang J and Li W: Cuproptosis correlates with
immunosuppressive tumor microenvironment based on pan-cancer
multiomics and single-cell sequencing analysis. Mol Cancer.
22:592023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zheng K, Hai Y, Chen H, Zhang Y, Hu X and
Ni K: Tumor immune dysfunction and exclusion subtypes in bladder
cancer and pan-cancer: A novel molecular subtyping strategy and
immunotherapeutic prediction model. J Transl Med. 22:3652024.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hu Y, Zheng M, Wang S, Gao L, Gou R, Liu
O, Dong H, Li X and Lin B: Identification of a five-gene signature
of the RGS gene family with prognostic value in ovarian cancer.
Genomics. 113:2134–2144. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yang Z, Wei X, Pan Y, Xu J, Si Y, Min Z
and Yu B: A new risk factor indicator for papillary thyroid cancer
based on immune infiltration. Cell Death Dis. 12:512021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yamamoto H and Hirasawa A: Homologous
recombination deficiencies and hereditary tumors. Int J Mol Sci.
23:3482021. View Article : Google Scholar
|
|
77
|
Villacampa G, Llop-Guevara A, Filmann N,
Herencia-Ropero A, Fasching PA, Karn T, Marmé F, Klare P, Müller V,
Stefek A, et al: RAD51 testing in patients with early HER2-negative
breast cancer and homologous recombination deficiency: A Post-Hoc
analysis of the GeparOLA trial. Clin Cancer Res. 31:808–814. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tao S, Pu Y, Yang EJ, Ren G, Shi C, Chen
LJ, Chen L and Shim JS: Inhibition of GSK3β is synthetic lethal
with FHIT loss in lung cancer by blocking homologous recombination
repair. Exp Mol Med. 57:167–183. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wagener-Ryczek S, Merkelbach-Bruse S and
Siemanowski J: Biomarkers for homologous recombination deficiency
in cancer. J Pers Med. 11:6122021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
van der Wiel AMA, Schuitmaker L, Cong Y,
Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A and Dubois LJ:
Homologous recombination deficiency scar: Mutations and
beyond-implications for precision oncology. Cancers (Basel).
14:41572022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hong CS, Ho W, Zhang C, Yang C, Elder JB
and Zhuang Z: LB100, a small molecule inhibitor of PP2A with potent
chemo- and radio-sensitizing potential. Cancer Biol Ther.
16:821–833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhou X, Ying H, Sun Y, Zhang W, Luo P, Zhu
S and Zhang J: Homologous recombination deficiency (HRD) is
associated with better prognosis and possibly causes a non-inflamed
tumour microenvironment in nasopharyngeal carcinoma. J Pathol Clin
Res. 10:e123912024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hong L, Li J and Shao W: A risk model
developed based on homologous recombination deficiency genes for
evaluating the drug sensitivity and prognostic prediction of lung
adenocarcinoma. Curr Med Chem. 32:6847–6866. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Liu C, Qian X, Yu C, Xia X, Li J, Li Y,
Xie Y, Gao G, Song Y, Zhang M, et al: Inhibition of ATM promotes
PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in
triple-negative breast cancer. Cancer Lett. 586:2166422024.
View Article : Google Scholar
|
|
85
|
Deng J, Zhang T, Liu F, Han Q, Li Q, Guo
X, Ma Y, Li L and Shao G: CRL4-DCAF8L2 E3 ligase promotes
ubiquitination and degradation of BARD1. Biochem Biophys Res
Commun. 611:107–113. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang Z, Zhao Y and Zhang L: Emerging
trends and hot topics in the application of multi-omics in drug
discovery: A bibliometric and visualized study. Current
Pharmaceutical Analysis. 21:20–32. 2024. View Article : Google Scholar
|
|
87
|
Chen J, Lin A and Luo P: Advancing
pharmaceutical research: A comprehensive review of cutting-edge
tools and technologies. Current Pharmaceutical Analysis. 21:1–19.
2024. View Article : Google Scholar
|
|
88
|
Liu JL, Yang M, Bai JG, Liu Z and Wang XS:
‘Cold’ colorectal cancer faces a bottleneck in immunotherapy. World
J Gastrointest Oncol. 15:240–250. 2023. View Article : Google Scholar
|
